Drugs / aIIV-B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05501561 | Aug 2022 → Mar 2023 | influenza | Seqirus | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | aIIV-B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05501561 ↗ |
| Modality | Vaccine | “Biological/Vaccine: Investigational aIIV-B Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine” NCT05501561 ↗ |